What is the translation of " ASTRAZENECA " in English?

• astrazeneca

Examples of using Astrazeneca in Croatian and their translations into English

Ime kompanije: AstraZeneca d.o.o.
Company name: AstraZeneca d.o.o.

Nositelj odobrenja za stavljanje lijeka u promet: AstraZeneca AB.
Marketing Authorisation Holder: AstraZeneca AB.

Proizvođač AstraZeneca GmbH Tinsdaler Weg 183.
Manufacturer AstraZeneca GmbH Tinsdaler Weg 183.

Kako se Cjepivo protiv pandemijske influence H5N1 AstraZeneca koristi?
How does Pandemic influenza vaccine H5N1 AstraZeneca work?

Astrazeneca je nositelj europskog patenta koji se odnosi na aktivni sastojak gefitinib.
Astrazeneca is the proprietor of a European patent covering the active ingredient gefitinib.

Što je Cjepivo protiv pandemijske influence H5N1 AstraZeneca i za što se koristi?
What is Pandemic influenza vaccine H5N1 AstraZeneca and what is it used for?

U prilog tome zahtjevu Astrazeneca je dostavila kliničke podatke nastale provedbom dvaju ispitivanja II. stadija.
In support of that application, Astrazeneca submitted clinical data from two Phase II studies.

Naziv i adresa proizvođača odgovornih za puštanje serije lijeka u promet AstraZeneca UK Limited.
Name and address of the manufacturers responsible for batch release AstraZeneca UK Limited.

Cjepivo protiv pandemijske influence H5N1 AstraZeneca je preventivno cjepivo za slučaj pandemije.
Pandemic influenza vaccine H5N1 AstraZeneca is a pandemic preparedness vaccine.

Svrha sažetka nije davati praktične savjete o primjeni Cjepiva protiv pandemijske influence H5N1 AstraZeneca.
It is not intended to provide practical advice on how to use Pandemic influenza vaccine H5N1 AstraZeneca.

Proizvođač: AstraZeneca UK Limited Silk Road Business Park Macclesfield, Cheshire, SK10 2NA Ujedinjeno Kraljevstvo.
Manufacturer: AstraZeneca UK Limited Silk Road Business Park Macclesfield, Cheshire, SK10 2NA United Kingdom.

Naziv lijeka promijenjen je u Cjepivo protiv pandemijske influence H5N1 AstraZeneca 24. svibnja 2017.
The name of the medicine was changed to Pandemic influenza vaccine H5N1 AstraZeneca on 24 May 2017.

Praktične informacije o primjeni Cjepiva protiv pandemijske influence H5N1 AstraZeneca bolesnici trebaju pročitati u uputi o cjepivu, odnosno obratiti se svom liječniku ili ljekarniku.
For practical information about using Pandemic influenza vaccine H5N1 AstraZeneca, patients should read the package leaflet or contact their doctor or pharmacist.

Ticagrelor(trgovački naziv Brilinta u SAD-u, Brilique i Possia u EU) inhibitor agregacije trombocita koji proizvodi AstraZeneca.
Ticagrelor(trade name Brilinta in the US, Brilique and Possia in the EU) is a platelet aggregation inhibitor produced by AstraZeneca.

To pokazuje da su se protutijela na Cjepivo protiv pandemijske influence H5N1 AstraZeneca značajno povećala kad su cijepljene odrasle osobe ponovo došle u kontakt s virusom.
This showed that antibodies against Pandemic influenza vaccine H5N1 AstraZeneca increased substantially when vaccinated adults came into contact with the virus again.

Nadalje, podaci nastali provedbom ispitivanja III. stadija za taj lijek nisu omogućili Astrazeneci da na zadovoljavajući način odgovori na pitanja koja je CHMP postavio tako da je u siječnju 2005. Astrazeneca povukla svoj zahtjev iz izdavanje OSP‑a.
Furthermore, the data generated by the Phase III studies submitted by the Astrazeneca did not enable it to provide satisfactory answers to the questions raised by the CHMP and, accordingly, Astrazeneca withdrew its MA application in January 2005.

Iako Cjepivo protiv pandemijske influence H5N1 AstraZeneca može pojačati piskanje pri disanju u djece u dobi od 1 do 2 godine, taj se rizik smatra prihvatljivim u vrijeme pandemije.
Although Pandemic influenza vaccine H5N1 AstraZeneca might increase wheezing in children aged 1 to 2 years, the risk is considered acceptable in a pandemic situation.

Preporuke i mjere opreza kojih se zdravstveni radnici i bolesnici trebaju pridržavati u cilju sigurne i učinkovite primjene Cjepiva protiv pandemijske influence H5N1 AstraZeneca nalaze se u sažetku opisa svojstava i u uputi o cjepivu.
Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Pandemic influenza vaccine H5N1 AstraZeneca have been included in the summary of product characteristics and the package leaflet.

Cjepivo protiv pandemijske influence H5N1 AstraZeneca cjepivo je razvijeno za zaštitu djece u dobi između 12 mjeseci i 18 godina starosti protiv influence(gripe) za vrijeme pandemije gripe.
Pandemic influenza vaccine H5N1 AstraZeneca is a vaccine developed to protect children aged between 12 months and 18 years against influenza(flu) during a flu pandemic.

Više informacija o suzbijanju gripe Cjepivom protiv pandemijske influence H5N1 AstraZeneca pročitajte u uputi o cjepivu(također dio EPAR-a), odnosno obratite se svom liječniku ili ljekarniku.
For more information about prevention of influenza with Pandemic influenza vaccine H5N1 AstraZeneca, read the package leaflet(also part of the EPAR) or contact your doctor or pharmacist.

Ako bi zbog takvog zahtjeva društvo AstraZeneca ili povezana društva mogla prekršiti svoje obveze prema primjenjivih zakonima, propisima ili kodeksima ponašanja, AstraZeneca možda neće moći ispuniti Vaš zahtjev, ali ćete ipak možda moći zatražiti da ograničimo uporabu Vaših osobnih podataka pri daljnjem obrađivanju.
If such a request places AstraZeneca or its affiliates in breach of its obligations under applicable laws, regulations or codes of practice, then AstraZeneca may not be able to comply with your request but you may still be able to request that we restrict the use of your personal data for further processing.

U tri glavna ispitivanja na 107 odraslih osoba utvrđeno je da je Cjepivo protiv pandemijske influence H5N1 AstraZeneca pripremilo imunosni sustav da se bori protiv soja virusa H5N1 u osoba koje mu prije nikad nisu bile izložene.
Three main studies involving 107 adults found that Pandemic influenza vaccine H5N1 AstraZeneca was able to prepare the immune system to defend itself against the H5N1 virus strain in individuals who had never come into contact with it.

Pandemic influenza vaccine H5N1 AstraZeneca(Pandemic influenza vaccine H5N1 Medimmune)(reassortant influenza virus(live attenuated)…)- Uvjeti ili ograničenja vezani uz opskrbu i primjenu- J07BB03.
Pandemic influenza vaccine H5N1 AstraZeneca(Pandemic influenza vaccine H5N1 Medimmune)(reassortant influenza virus(live attenuated)…)- Conditions or restrictions regarding supply and use- J07BB03.

Odlukom Europske komisije od 8. rujna 2016. godine za lijek Caprelsa je odobren prijenos nositelja odobrenja s AstraZeneca AB na Genzyme Europe BV, čime je kompanija Sanofi preuzela sva prava vezano uz lijek Caprelsa Genzyme Europe BV je dio Sanofi grupe.
By the decision of the European Commission on 8 September 2016, the transfer of marketing authorisation for Caprelsa from AstraZeneca AB to Genzyme Europe BV has been approved, by which the company Sanofi acquired all rights related to Caprelsa Genzyme Europe BV is a part of Sanofi Group.

Ako ste bolesnik koji prijavljuje nuspojavu, AstraZeneca će možda prikupiti osjetljive osobne podatke o Vama, uključujući informacije o Vašem tjelesnom ili metalnom zdravlju, u sklopu procesa prijavljivanja i praćenja nuspojave koju ste prijavili.
If you are a Patient reporting adverse event, AstraZeneca may obtain sensitive personal data about you, including details about your physical or mental health, as part of the reporting process and tracking the side effect case you reported.

U osoba koje su primile drugo cjepivo u razdoblju od tri tjedna do pet godina nakon cijepljenja Cjepivom protiv pandemijske influence H5N1 AstraZeneca, protutijela su se povećala četiri puta u 73%(8 od 11) osoba, u usporedbi s 10% osoba koje prethodno nisu bile cijepljene Cjepivom protiv pandemijske influence H5N1 AstraZeneca.
In those who received the second vaccine 3 weeks to 5 years after vaccination with Pandemic influenza vaccine H5N1 AstraZeneca, antibodies increased 4-fold in 73%(8 out of 11) of the individuals compared with 10% of the individuals who had not been previously vaccinated with Pandemic influenza vaccine H5N1 AstraZeneca.

Nadalje, što se tiče argumenta koji Astrazeneca izgleda ističe, to jest da u stvarnosti nije imala vremena niti prilike distribuirati lijek Iressu na području Kneževine Lihtenštajna, države stranke EGP‑a, valja ustvrditi da isti nije relevantan.
Moreover, the argument that Astrazeneca would appear to have put forward- to the effect that it has not in fact had the time or the opportunity actually to market Iressa in the Principality of Liechtenstein, an EEA State- is clearly irrelevant.

Najčešće nuspojave Cjepiva protiv pandemijske influence H5N1 AstraZeneca(koje se mogu javiti u više od 1 na 10 osoba) su smanjeni apetit, glavobolja, hunjavica ili začepljen nos i opće loše stanje.
The most common side effects with Pandemic influenza vaccine H5N1 AstraZeneca(which may affect more than 1 in 10 people) are decreased appetite, headache, runny or stuffy nose, and feeling unwell.

Cjepivo protiv pandemijske influence H5N1 AstraZeneca u pravilu se ne smije davati djeci koja su imala jake alergijske reakcije na bilo koji sastojak cjepiva, uključujući želatinu i gentamicin, niti djeci koja su imala jake alergijske reakcije na jaja i bjelančevine jaja, poput ovalbumina.
Pandemic influenza vaccine H5N1 AstraZeneca must not generally be given to children who have had a severe allergic reaction to any of the substances in the vaccine including gelatin and gentamicin or to children who have had a severe allergic reaction to eggs or egg proteins, such as ovalbumin.

Slično podacima iz VAERS-a, u izvještajima za 113 trudnica koje su primile AstraZeneca 2009 monovalentno živo cjepivo(H1N1) za intranazalnu primjenu, nisu zabilježeni neuobičajeni oblici komplikacija u trudnoći ili fetalnih ishoda.
Similarly from the VAERS, in 113 reports of pregnant women who had received AstraZeneca's(H1N1) 2009 Monovalent Vaccine Live, Intranasal, no unusual patterns of pregnancy complications or foetal outcomes were observed.